Abstract
The aim of this study was to evaluate the polymorphisms of human leukocyte antigen (HLA) and Duffy erythrocyte antigen in nephropathic patients from southern Brazil. One hundred and eighty three chronic kidney patients from southern Brazil participated in this study. HLA typing was performed using the LABType SSO kits locus HLA-A, -B and-DRB1 (One Lambda, Inc.). Duffy phenotypes were defined by the gel agglutination method using monoclonal anti-Fya and anti-Fyb antisera. Fisher’s exact test was employed for statistical analysis. Odds Ratio (OR) and Confidence Interval (CI) at 95% were calculated. Data from other studies with healthy individuals (voluntary bone marrow donors) were used for the comparison of analysis. In the analysis of the total samples, Fy(a+b+) phenotype was the most frequent (35%) and Fy(a-b-) phenotype was the rarest (5%). Nineteen HLA-A, 30 HLA-B and 13 HLA-DRB1 allele groups were identified. The 15 most frequent HLA allele groups were HLA-A∗01, A∗02, A∗03, A∗11, A∗24, HLA-B∗07, B∗15, B∗35, B∗44, B∗51, HLA-DRB1∗03, DRB1∗04, DRB1∗07, DRB1∗11 and DRB1∗13. The frequencies of Fy(a+b-) and Fy(a+b+) phenotypes of this study compared with healthy individuals from the same region, showed statistically significant difference with p <0.0001, OR = 2.56 (95% CI = 1.60-4.07) and p = 0.0039, OR = 1.71 (95% CI = 1.18-2.51), respectively. When comparing the HLA allele frequencies of patients and healthy individuals, it was observed that HLA-B∗42, B∗45, B∗51, DRB1∗03 were more frequent in patients and HLA-B∗44 in healthy individuals (p < 0.05). The polymorphism of these two markers when compared between the nephropathic patients from southern Brazil and other studies, suggest that the Duffy antigen and HLA allele groups may be engaged with chronic kidney disease (CKD). Further studies are needed to evaluate the influence of these markers in the evolution of CKD, as well as the evolution of transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
